Cough – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Cough – Pipeline Review, H1 2017’, provides an overview of the Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cough

– The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cough therapeutics and enlists all their major and minor projects

– The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cough

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cough

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Afferent Pharmaceuticals Inc

Alitair Pharmaceuticals Inc

Alveonix AG

AstraZeneca Plc

BELLUS Health Inc

Charleston Laboratories Inc

Conrig Pharma ApS

Daewoong Pharmaceutical Co Ltd

Hyundai Pharmaceutical Co Ltd

NeRRe Therapeutics Ltd

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

Pila Pharma AB

Vernalis Plc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cough Overview

Cough Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cough Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cough Companies Involved in Therapeutics Development

Afferent Pharmaceuticals Inc

Alitair Pharmaceuticals Inc

Alveonix AG

AstraZeneca Plc

BELLUS Health Inc

Charleston Laboratories Inc

Conrig Pharma ApS

Daewoong Pharmaceutical Co Ltd

Hyundai Pharmaceutical Co Ltd

NeRRe Therapeutics Ltd

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

Pila Pharma AB

Vernalis Plc

Cough Drug Profiles

AF-219 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-8 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzonatate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-5937 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-05 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-06 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-07 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-08 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLAT-313 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

codeine + guaifenesin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-1340 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin + hydrocodone Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lesogaberan Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levodropropizine CR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORB-110 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orvepitant maleate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHCA-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1226 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-015 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-016 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-018 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEND-0501 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cough Dormant Projects

Cough Discontinued Products

Cough Product Development Milestones

Featured News & Press Releases

Dec 21, 2016: FDA accepts CCP-08 NDA for full review

Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis

Sep 06, 2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review

Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study

May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference

May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors

Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference

Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study

Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study

Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study

Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing

Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial

Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine

Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing

Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cough, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Cough Pipeline by Afferent Pharmaceuticals Inc, H1 2017

Cough Pipeline by Alitair Pharmaceuticals Inc, H1 2017

Cough Pipeline by Alveonix AG, H1 2017

Cough Pipeline by AstraZeneca Plc, H1 2017

Cough Pipeline by BELLUS Health Inc, H1 2017

Cough Pipeline by Charleston Laboratories Inc, H1 2017

Cough Pipeline by Conrig Pharma ApS, H1 2017

Cough Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Cough Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Cough Pipeline by NeRRe Therapeutics Ltd, H1 2017

Cough Pipeline by Orbis Biosciences Inc, H1 2017

Cough Pipeline by Patara Pharma Inc, H1 2017

Cough Pipeline by PhytoHealth Corp, H1 2017

Cough Pipeline by Pila Pharma AB, H1 2017

Cough Pipeline by Vernalis Plc, H1 2017

Cough Dormant Projects, H1 2017

Cough Dormant Projects, H1 2017 (Contd..1), H1 2017

Cough Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Cough, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports